US20220152413A1 - Method and device for gut microbiota manipulation - Google Patents
Method and device for gut microbiota manipulation Download PDFInfo
- Publication number
- US20220152413A1 US20220152413A1 US17/436,222 US202017436222A US2022152413A1 US 20220152413 A1 US20220152413 A1 US 20220152413A1 US 202017436222 A US202017436222 A US 202017436222A US 2022152413 A1 US2022152413 A1 US 2022152413A1
- Authority
- US
- United States
- Prior art keywords
- canceled
- illumination
- protocol
- bacterial species
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000005709 gut microbiome Species 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000001580 bacterial effect Effects 0.000 claims abstract description 84
- 230000012010 growth Effects 0.000 claims abstract description 32
- 238000005286 illumination Methods 0.000 claims description 84
- 241000894007 species Species 0.000 claims description 81
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 65
- 230000002550 fecal effect Effects 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000011065 in-situ storage Methods 0.000 claims description 10
- 230000000975 bioactive effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 238000002054 transplantation Methods 0.000 claims description 7
- 244000005702 human microbiome Species 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 230000009747 swallowing Effects 0.000 claims description 6
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 5
- 235000020932 food allergy Nutrition 0.000 claims description 5
- 208000037384 Clostridium Infections Diseases 0.000 claims description 4
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 4
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000027244 Dysbiosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010033307 Overweight Diseases 0.000 claims description 4
- 206010036774 Proctitis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 4
- 230000007140 dysbiosis Effects 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 235000020825 overweight Nutrition 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 67
- 238000011282 treatment Methods 0.000 description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 15
- 244000005700 microbiome Species 0.000 description 13
- 241000193163 Clostridioides difficile Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000000813 microbial effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000736262 Microbiota Species 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001112693 Lachnospiraceae Species 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 4
- 229950011318 cannabidiol Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 4
- 229960004242 dronabinol Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 229930003827 cannabinoid Natural products 0.000 description 3
- 239000003557 cannabinoid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 108010022678 Phosphofructokinase-2 Proteins 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 241000605947 Roseburia Species 0.000 description 2
- 241000123710 Sutterella Species 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 2
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- YSEKNCXYRGKTBJ-UHFFFAOYSA-N dimethyl 2-hydroxybutanedioate Chemical compound COC(=O)CC(O)C(=O)OC YSEKNCXYRGKTBJ-UHFFFAOYSA-N 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 231100000033 toxigenic Toxicity 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical class C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- CSCOJWVRGOZGPK-UHFFFAOYSA-N 3-[[2-[4-(2-adamantyl)phenoxy]-1-oxoethyl]amino]-4-hydroxybenzoic acid methyl ester Chemical compound COC(=O)C1=CC=C(O)C(NC(=O)COC=2C=CC(=CC=2)C2C3CC4CC(C3)CC2C4)=C1 CSCOJWVRGOZGPK-UHFFFAOYSA-N 0.000 description 1
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241001227086 Anaerostipes Species 0.000 description 1
- 241001013579 Anaerotruncus Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000217846 Bacteroides caccae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001464949 Coprococcus eutactus Species 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 241000500134 Dehalobacterium Species 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241001531200 Dorea formicigenerans Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229940123469 Fatty acid synthase inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000015929 Fructose-2,6-bisphosphatases Human genes 0.000 description 1
- 241001135750 Geobacter Species 0.000 description 1
- 241000204888 Geobacter sp. Species 0.000 description 1
- 229940123538 Glucose-6 phosphate dehydrogenase inhibitor Drugs 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 229940122084 Hexokinase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102100030481 Hypoxia-inducible factor 1-alpha inhibitor Human genes 0.000 description 1
- 101710081472 Hypoxia-inducible factor 1-alpha inhibitor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710108550 NAD-dependent malic enzyme, mitochondrial Proteins 0.000 description 1
- 102100032457 NAD-dependent malic enzyme, mitochondrial Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 241001216709 Parabacteroides gordonii Species 0.000 description 1
- 241001267970 Paraprevotella Species 0.000 description 1
- 102000012434 Phosphofructokinase-2 Human genes 0.000 description 1
- JFACETXYABVHFD-WXPPGMDDSA-N Pristimerin Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C[C@H]53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-WXPPGMDDSA-N 0.000 description 1
- FMPJNBPZCVETGY-UHFFFAOYSA-N Pristimerinen Natural products C12=CC=C3C(C)=C(O)C(=O)C=C3C2=C(C)CC2(C)C1(C)CCC1(C)CCC(C(=O)OC)(C)CC12 FMPJNBPZCVETGY-UHFFFAOYSA-N 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 229940124117 Pyruvate dehydrogenase inhibitor Drugs 0.000 description 1
- 229940122106 Pyruvate dehydrogenase kinase inhibitor Drugs 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000605944 Roseburia cecicola Species 0.000 description 1
- 241000872831 Roseburia faecis Species 0.000 description 1
- 241000872832 Roseburia hominis Species 0.000 description 1
- 241000398180 Roseburia intestinalis Species 0.000 description 1
- 241001394655 Roseburia inulinivorans Species 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 241000202356 Ruminococcus lactaris Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 241000096798 Sutterella parvirubra Species 0.000 description 1
- 241000644554 Sutterella stercoricanis Species 0.000 description 1
- 241000123713 Sutterella wadsworthensis Species 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229940122852 Transketolase inhibitor Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004819 isoxsuprine Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126127 monocarboxylate transporter inhibitor Drugs 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 229930003811 natural phenol Natural products 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- IXWGHMMOEFOOFA-UHFFFAOYSA-N pristimerin Natural products COC(=O)C1(C)CCC2(C)CCC3(C)C4CC=C5C(=C(O)C(=O)C=C5C4(C)CCC3(C)C2C1)C IXWGHMMOEFOOFA-UHFFFAOYSA-N 0.000 description 1
- JFACETXYABVHFD-UHFFFAOYSA-N pristimerine Natural products CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-UHFFFAOYSA-N 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 101150032575 tcdA gene Proteins 0.000 description 1
- 101150089436 tcdB gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 description 1
- 229950002860 triplatin tetranitrate Drugs 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- -1 vasomodulators Chemical compound 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
Definitions
- the term “manipulating” refers, without limitation, to influencing the composition of bacterial species populations. In one embodiment, the term “manipulating” refers to inhibiting the growth of at least one of the plurality of the bacterial species. In another embodiment, the term “manipulating” refers to eliminating at least one bacterial species in the sample. In yet another embodiment, the term “manipulating” refers to enhancing the growth of at least one bacterial species in the sample. As used herein, the term “protocol” refers, without limitation, to a predetermined set of conditions combination of which is designed to lead to a desired outcome.
- the protocol comprises at least one of the following: comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, presence of bioactive substance, or any combination thereof.
- a non-limiting medicines for combating inflammation, fibrosis, hyperglycolisis, such as diabetic nephropathy comprises naturally derived ubiquitous phenolic compounds, such as ferulic acid, natural phenols, for example resveratrol, rutin, quercetin, phenolic acids, vitamins, and allicin, cannabinoids selected from the group consisting of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), cannabinolic acid (CBNa) cannabichromenic acid (CBCa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD) and cannabichromene (CBC) or/and the derivatives of thereof, and synthetic analogues, dexmedetomidine, ( ⁇ 2-AR) agonist, metabolic protectants, including, without limitation, vildagliptin, pristimerin, metformin, pyri
- the protocol comprises at least two illumination episodes. In yet another embodiment, the protocol comprises a sequence of illumination episodes. In another embodiment, similar wavelength is used in each illumination episode. In yet further embodiment, at least two illumination episodes are carried out at different wavelengths.
- the protocol of the invention may involve as many illumination episodes as needed, at different or identical wavelengths and for the desired duration of time. Any combination of illumination at the indicated wavelengths with other parameters constitute an integral part of the present invention.
- the protocol is designed to generate a specific profile of a plurality of bacterial species in the sample. Reference is now made to FIG.
- FIG. 1 illustrating an exemplary embodiment of a heatmap presenting a profile of gut micro-organisms in a fecal sample at the genus level following illumination episodes with respect to the wavelength.
- Horizontal lines represent the relative abundance of major genera that exhibited at least 50% change relative to control. The bacterial abundance of each genus is expressed in standard deviation units scaled internally on a row basis and represented by color key.
- Hierarchical clustering was based on Euclidian distance measure and Word's agglomeration method. Side bars show the taxonomic classification of the different genera in the phylum, class, order and family level.
- a non-limiting list of gut micro-organisms in the sample comprises: bacterial species of Roseburia genus; Sutterella genus; Prevotella genus; Haemophilus genus; Anaerotruncus genus; Geobacter genus; Neisseria genus; Pseudomonas genus; Paraprevotella genus; Anaerostipes genus; Dehalobacterium genus; Coprococcus eutactus; Ruminococcus genus; Bifidobacterium longum; Dorea formicigenerans; Bacteroides caccae ; and Parabacteroides gordonii .
- the genus Roseburia which consists of obligate gram-positive anaerobic bacterial species and includes five species: R. intestinalis, R. hominis, R. inulinivorans, R. faecis and R. americancola , was increased in 440 nm treatment.
- the genus Sutterella which represents gram negative anaerobic bacteria and includes three species: S. parvirubra, S. stercoricanis and S. wadsworthensis was increased in 660 nm and 880 nm treatments.
- the genus Prevotella which includes almost 40 different species with a large genomic diversity was increased in 660 nm and 880 nm treatments.
- the Geobacter species, Neisseria genus, and Pseudomonas genus, were reduced under all illumination treatments.
- the protocol is designed to enrich at least one microorganism genus in-vitro and/or in-vivo and/or in-situ.
- the term “to enrich” refers, without limitation, to an increase in the proportion of a particular bacterial genus and/or species in the sample.
- the protocol is designed to enrich at least one bacterial species.
- the protocol is designed to enrich at least one bacterial genus.
- the protocol is designed to increase the growth of at least one bacterial species and/or genus and to inhibit the growth of at least one bacterial species and/or genus at the same time.
- the protocol is designed to increase the growth of more than one bacterial species and/or genii and to inhibit growth of more than one bacterial species and/or genii at the same time. In one embodiment, the protocol is designed to eliminate at least one bacterial species and/or genii. In one embodiment, the protocol is designed to downsize at least one bacterial species and/or genii. In one embodiment, the protocol is designed to obtain a human gut microbiota sample having a desired profile of bacterial species and/or genii. In one embodiment, the protocol. In one embodiment of the invention, the protocol is designed to selectively enhance, reduce or eliminate microorganism species from the sample to obtain a human gut microbiota sample having a desired profile. As used herein, the term “profile” refers, without limitation, to an information relating to characteristics of the sample based on quantification of bacterial species populations constituting the gut microbiota sample.
- the invention further provides A method for obtaining a sample having a desired profile of bacterial species of gut microbiota, the method comprising:
- the at least one protocol comprises at least two illumination episodes. In another embodiment, the at least one protocol comprises a sequence of multiple illumination episodes. In one embodiment, the wavelength of illumination is similar in each episode. In one embodiment, the wavelength of illumination is similar in each episode. In one embodiment, the wavelength of illumination is similar in each episode. In another embodiment, the illumination episodes are carried out at least two different wavelengths. In one embodiment, the at least one protocol is designed to enhance the growth of at least one bacterial species population in the starting sample. In another embodiment, the at least one protocol is designed to inhibit the growth of at least one bacterial species population in the starting sample. In another embodiment, the at least one protocol is designed to eliminate the growth of at least one bacterial species population in the starting sample.
- the starting sample subjected to at least two protocols.
- the at least two protocols are designed to manipulate growth of different bacterial species populations in the starting sample.
- the wavelength is 420-460 nm; 640-680 nm; and 830-870 nm.
- the at least one protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
- the invention provides a system for manipulating human gut microbiota in-situ comprising:
- the controller is configured to deliver two or more protocols for manipulating gut microbiota at the desired location.
- the two or more protocols are delivered at the same location of the GI tract of the human subject.
- the two or more protocols are delivered at different locations of the GI tract.
- the controller is configured to deliver a plurality of protocols.
- the plurality of protocols is delivered at different locations of the GI tract of the subject.
- the invention further provides a method for treating a disorder in a human subject by manipulating gut microbiota, the method comprising:
- the swallowable vehicle comprises at least one reservoir configured to carry and release a cargo.
- the step of loading the sample derived from gut microbiota to the reservoir precedes step d.
- the method further comprising the step of releasing the sample derived from human gut microbiota or a portion thereof at the desired location of the GI tract of the subject.
- the step of releasing the sample precedes step e.
- the step of releasing the sample follows step e.
- the protocol comprises multiple illumination episodes.
- the software operated controller is configured to fulfill at least one of the following functions: regulating the function of the light emitting unit, regulating the motion of the vehicle, identifying the location of the vehicle, instructing the vehicle to reach a desired location of the GI tract; delivering the at least one protocol for manipulating the gut microbiota at the desired location, and, actuating release of the cargo from the at least one reservoir at the desired location.
- the protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
- the non-limiting list of disorders of the invention includes: Inflammatory Bowel Diseases, Crohn Disease, Type II Diabetes, HIV, malignancy of GI tract, Ulcerative Colitis, Proctitis, Over-weight, Irritable Bowel syndrome, Alzheimer, depression, Celiac, Specific food allergies, Clostridium Difficile infection, Diarrhea, Chronic constipation, and Dysbiosis.
- the invention further provides a method of fecal transplantation in a subject comprising:
- the term “preparing a fecal sample” refers, without limitation, to subjecting the fecal sample to at least one protocol of the invention to obtain a sample having desired profile of bacterial species.
- the method of fecal transplantation further comprises a step of delivery of at least one protocol for manipulating gut microbiota.
- the protocol comprises at least one episode of illuminating the GI tract of the subject at the wavelength in the range of 400 nm to 900 nm. In one embodiment, the protocol comprises multiple illuminating episodes.
- the protocol comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, presence of bioactive substance, or a combination thereof.
- the subject is afflicted with a disorder characterized by impaired gut microbiota.
- disorders characterized by impaired gut microbiota includes: Inflammatory Bowel Diseases, Crohn Disease, Type II Diabetes, HIV, malignancy of GI tract, Ulcerative Colitis, Proctitis, Over-weight, Irritable Bowel syndrome, Alzheimer, depression, Celiac, Specific food allergies, Clostridium Difficile infection, Diarrhea, Chronic constipation, and Dysbiosis.
- the objective of the study was to test the effect of three different wavelengths of low-level light therapy on fecal microbiota composition in-vitro.
- Sample size 10 fecal samples were tested for each regimen. A total of 40 tested samples+original pre-plated uncultured sample.
- Illumination was performed in 5 exposures, where in each day, 2 exposures were performed (same time every day, at least 8 hr. interval between exposures. i.e. 8:00 am and 16:00 pm) for 2.5 days within the anaerobic chamber. After the 5th exposure, a 6-hour duration between illumination and bacterial harvesting is required. Illumination device was held in a specific pre-defined distance from the plate (using a special holder), in order to equally expose all the plate surface.
- Toxigenic strain of C. difficile that expresses both the tcdA and tcdB genes required for the production of toxin A and toxin B Clostridioides difficile (Prevot) Lawson et al. (ATCC® 43255TM) that belongs to toxinotype 0 was used.
- C. difficile inhibition was compared to a reference beneficial species such as Bifidobacterium longum that was reported to reduce mucosal inflammation marker in IBD (can be grown on MRS at 37° C. anaerobically) 3
- FIG. 2 demonstrates that the treatment (660 nm & 850 nm) induces significant alternations in microbiota composition compared to the control.
- PCoA principal coordinates analysis
- presenting microbiota composition was used to assess microbial composition dissimilarity based on Bray-Curtis distance. Each point represents the bacterial composition profile of the different tested treatment protocols: 440 nm wavelength (blue); 660 nm (orange); 850 nm (red) and untreated sample as a control (dark green). Numbers indicated different fecal donors.
- B Boxplots comparing PC1 and PC2 coordinates between the different treatments. The results demonstrate that the treatment (660 nm & 850 nm) induces significant alternations in microbiota composition compared to the control, as indicated from the significant difference in PC2 coordinates values.
- FIG. 3 demonstrates that the treatment increases the microbial diversity of IBD samples using alpha diversity (community richness) rarefaction plots by treatment.
- Microbial alpha diversity was assessed using rarefaction plots to compare samples from the different treatments and control using the Faith's Phylogenetic Diversity estimate. Error bars correspond to variations between samples of each treatment group.
- (A) 440 nm treatment induces increase in microbial diversity in IBD samples.
- B 660 nm treatment induces increase in microbial diversity in IBD samples.
- C 850 nm treatment has no significant effect on alpha diversity. Healthy samples were not affected due to already high baseline diversity. The results indicate that the 440 nm and the 660 nm treatments induce increase in the microbial diversity of samples from IBD patients to similar level of samples from healthy donors.
- FIG. 4 demonstrates that the treatment increases the microbial diversity of IBD samples.
- Microbial alpha diversity was assessed using rarefaction plots to compare samples from the different treatments and control using the observed OTU (Operational Taxonomic Units) estimate, which represent the count of unique OTUs in each sample. Error bars correspond to variations between samples of each treatment group.
- OTU Operaational Taxonomic Units
- (A) 440 nm treatment induces increase in microbial diversity in IBD samples.
- B 660 nm treatment has no significant effect on alpha diversity.
- C 850 nm treatment has no significant effect on alpha diversity. Healthy samples are not affected due to already high baseline diversity. The results indicate that the 440 nm and the 660 nm treatments induce increase in the microbial diversity of samples from IBD patients to similar level of samples from healthy donors.
- FIG. 5 illustrates treatment differentially abundant species. Boxplots comparing the normalized relative abundance levels of differentially abundant species between treatment samples and controls. The normalization was performed by first calculation of relative abundance of each species within each sample multiply by factor 1000. Only samples that had non-zero counts in the control untreated group, in at least 30% of the samples were included. Differential abundance was estimated using paired Wilcoxon test between treated samples vs controls. The results demonstrate a significant increase in the Lachnospiraceae sp. and Ruminococcus lactaris abundances following 440 nm and 660 nm treatments. Lachnospiraceae and Ruminococcaceae were known to be positively associated with healthy individuals. Some species of the Lachnospiraceae family are butyrate producers; butyrate production in the human gut is highly relevant as it promotes Treg cell differentiation which can ultimately suppress pro-inflammatory responses.
- FIG. 6 illustrates treatment differential abundance—Family level. Boxplots comparing the normalized relative abundance levels of differentially abundant bacteria in the family level between treatment samples and controls. The normalization was performed by first calculation of relative abundance of each species within each sample multiply by factor 1000. Only samples that had non-zero counts in the control untreated group, in at least 30% of the samples were included. Differential abundance was estimated using paired Wilcoxon test between treated samples vs controls. The results indicate a significant increase in the abundance of the Lachnospiraceae family following 440 nm and 660 nm treatments. Lachnospiraceae are important short-chain fatty acids producers.
- terms such as, for example, “processing”, “computing”, “calculating”, “determining”, “establishing”, “analyzing”, “checking”, or the like may refer to operation(s) and/or process(es) of a computer, a computing platform, a computing system, or other electronic computing device, that manipulates and/or transforms data represented as physical (e.g., electronic) quantities within the computer's registers and/or memories into other data similarly represented as physical quantities within the computer's registers and/or memories or other information non-transitory storage medium that may store instructions to perform operations and/or processes.
- a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range.
- description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range.
- the phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
- method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- patient or “subject” is meant to include any mammal.
- Treating” or “treatment” of a disease as used herein includes: preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms, or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Radiation-Therapy Devices (AREA)
- Laser Surgery Devices (AREA)
- Medicinal Preparation (AREA)
- Endoscopes (AREA)
Abstract
The present disclosure generally provides systems and methods for manipulating bacterial growth, abundance and diversity in biological sample. More particularly, the present invention relates to systems and methods for manipulating gut microbiota.
Description
- The present disclosure generally relates to the field of systems and methods for manipulating bacterial growth and abundance in biological sample. More particularly, the present invention relates to systems and methods for manipulating gut microbiota.
- Over the recent years many efforts have been invested in understanding the link between gut microbiota and health. It was clearly shown that changing the composition of gut resident micro-organisms might have a profound effect on certain health conditions. Based on the scientific evidences accumulated so far and an ongoing research, it seems that the ability to selectively manage the composition of microorganisms in the GI tract, could have an impact of various diseases and be instrumental in treatment. Moreover, it has been demonstrated that adding specific bacteria as food supplement is insufficient. The entire population of micro-organisms inside the GI tract which comprises wide variety of species, which is referred to as gut microbiota, should be taken into consideration, to make an impact. Thus, the ability to control the composition of the gut microbiota, by enriching specific populations of micro-organisms has strong therapeutic potential. Indeed, maintaining biological diversity in the GI tract has been shown beneficial for various food allergies, inflammatory diseases of the GI tract, diabetes and obesity.
- Given the diversity of gut microbiota and the complexity of human GI tract as therapeutic target, there is an unmet need in effective, accessible, easy-to-use therapeutic tools for manipulating human gut microbiota.
-
FIG. 1 : illustrates a heatmap presenting a profile of gut micro-organisms in a fecal sample; -
FIG. 2 : illustrates Principal Coordinates Analysis (PCoA) presenting microbiota composition; -
FIG. 3 : illustrates Alpha diversity (community richness) rarefaction plots by treatment using Faith's Phylogenetic Diversity estimate; -
FIG. 4 : illustrates Alpha diversity (community richness) rarefaction plots by treatment using observed OTU (Operational Taxonomic Units) estimate; -
FIG. 5 : illustrates boxplots comparing the normalized relative abundance levels of differentially abundant species between treatment samples and controls; and -
FIG. 6 : illustrates boxplots comparing the normalized relative abundance levels of differentially abundant bacteria in the family level between treatment samples and controls. - Accordingly, it is a principal object of the present invention to providing an efficient system and method for manipulating human gut microbiota inside and outside the Gastrointestinal (GI) tract and use of such system as potential therapeutic tool. The invention provides a method for manipulating the growth of a plurality of bacterial species of gut microbiota comprising subjecting the plurality of bacterial species to at least one protocol, wherein said protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm.
- The invention further provides a method for obtaining a sample having a desired profile of bacterial species of gut microbiota, the method comprising:
-
- a) providing a starting sample of bacterial species of gut microbiota;
- b) determining the profile of the bacterial species in the starting sample of gut microbiota;
- c) selecting at least one protocol designed to manipulate the growth of bacterial species, wherein said protocol comprises a predefined set of conditions, and, wherein said predefined set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
- d) subjecting the starting sample to the at least one protocol; and, optionally,
- e) determining the profile of the bacterial species in the sample.
- The invention further provides a system for manipulating human gut microbiota in-situ comprising:
-
- a) a sample of human microbiota having desired bacterial species profile;
- b) a swallowable vehicle configured to move through the GI tract of a human subject, wherein said vehicle comprises at least one light emitting unit, and at least one reservoir configured to carry and release the sample of human microbiota;
- c) at least one protocol for manipulating the gut microbiota, wherein said protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
- d) a software operated controller configured to control the vehicle; and,
- e) a software configured to upload the at least one predefined set of conditions to the software operated controller.
- The invention yet further provides a method for treating a disorder in a human subject by manipulating gut microbiota, the method comprising:
-
- a) providing a system for manipulating human gut microbiota in-situ, wherein said system comprises a swallowable light emitting vehicle configured to move through the GI tract of a human subject; a software; a software operated controller and a plurality of protocols for manipulating the gut microbiota, wherein each protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
- b) Selecting at least one of the plurality of protocols for manipulating gut microbiota suitable for treating the disorder;
- c) uploading said at least one protocol to the software operated controller of the vehicle;
- d) swallowing the vehicle; and
- e) delivering the at least one protocol for manipulating gut microbiota at a desired location of the GI tract of the subject.
- The invention yet further provides method of fecal transplantation in a subject comprising:
-
- a) preparing a fecal sample suitable for transplantation at the GI tract of the subject
- b) providing a swallowable vehicle configured to move through the GI tract of a human subject, wherein said vehicle comprises at least one light emitting unit, a software operated controller, and at least one reservoir configured to carry and release the fecal sample;
- c) loading the reservoir with the fecal sample;
- d) programming the software operated controller to deliver the fecal sample to a desired location in the GI tract;
- e) swallowing the vehicle; and,
- f) releasing the fecal sample at the desired location of the GI tract.
- Additional features and advantages of the invention will become apparent from the following drawings and description.
- Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description, examples or illustrated in the drawings. The invention is applicable to other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
- The invention provides a method for manipulating the growth of a plurality of bacterial species of gut microbiota comprising subjecting the plurality of bacterial species to at least one protocol, wherein said protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm. As used herein, the term “plurality” refers, without limitation to a large number of different types of microorganisms associated with the gut. The term “plurality”, in the context of the invention can be understood as “diversity” of the bacterial species in the gut. The term “gut microbiota” as used herein, is meant to be understood without limitation as a total of micro-organisms residing and/or associated with the GI tract or the gut in healthy and/or diseased state. According to some embodiments, manipulating the growth of the plurality of bacterial species of gut microbiota comprises obtaining a sample of gut microbiota from a subject and, subjecting said sample to the at least one protocol comprising at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm. According to some embodiments, manipulating the growth of the plurality of bacterial species of gut microbiota is done in-situ and comprises subjecting at least a portion of GI tract of a subject to the at least one protocol comprising at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm. The phrase “at least a portion of GI tract” is meant to be understood, without limitation, as a region or a part either small part or a large part, including, without limitation, stomach, small or large intestine of the gastrointestinal tract of the subject. To avoid any doubt, more than one portion of the GI tract can be subjected to the method of the invention. In one embodiment, manipulating the growth of the plurality of bacterial species of gut microbiota is done in-situ and comprises subjecting more than one portion of GI tract of the subject to the at least one protocol comprising at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm. In another embodiment, a single portion of the GI tract is subjected to one or more protocols. In one embodiment, a single portion of the GI tract is repeatedly subjected to a single protocol. In yet another embodiment, a single portion of the GI tract is subjected to multiple protocols. According to some embodiments, a portion and/or portions of the GI tract of the subject may be subjected to one and/or multiple protocols, in any order or any combination suitable to achieve the desired effect. As used herein, the term “manipulating” refers, without limitation, to influencing the composition of bacterial species populations. In one embodiment, the term “manipulating” refers to inhibiting the growth of at least one of the plurality of the bacterial species. In another embodiment, the term “manipulating” refers to eliminating at least one bacterial species in the sample. In yet another embodiment, the term “manipulating” refers to enhancing the growth of at least one bacterial species in the sample. As used herein, the term “protocol” refers, without limitation, to a predetermined set of conditions combination of which is designed to lead to a desired outcome. In one embodiment, the protocol comprises at least one of the following: comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, presence of bioactive substance, or any combination thereof. As used herein, the term “bioactive substance” refers, without limitation to signaling molecules, biomolecules; genetic and translation modifying nucleic material; deoxyribonucleic acids (DNA); ribonucleic acids (RNA); organic molecules; inorganic molecules; amino acids; vitamins; polyphenol, steroid, lipophilic poor soluble drug, vasomodulators; peptides; neurotransmitters and analogues of thereof; nucleosides; proteins, including without limitation growth factors, hormones, aptamers, antibodies, cytokines, enzymes, and heat shock proteins; cannabinoid; cannabinoid acid such as tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), cannabinolic acid (CBNa) cannabichromenic acid (CBCa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), and cannabichromene (CBC), and endocannobinoids and their analogues, or any other molecules that can exert biological function. As used herein, the term “medication” refers to a substance having a therapeutic effect. As used herein, the term “therapeutic effect” refers, without limitation to response(s) after a treatment of any kind, the results of which are judged to be useful or favorable. This is true whether the result was expected, unexpected, or even an unintended consequence. In one embodiment, the therapeutic effect is selected from the group consisting of anti-inflammatory effect, anti-fibrotic effect, anti-tumor effect, and neuroprotective effect. A non-limiting medicines for combating inflammation, fibrosis, hyperglycolisis, such as diabetic nephropathy, comprises naturally derived ubiquitous phenolic compounds, such as ferulic acid, natural phenols, for example resveratrol, rutin, quercetin, phenolic acids, vitamins, and allicin, cannabinoids selected from the group consisting of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), cannabinolic acid (CBNa) cannabichromenic acid (CBCa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD) and cannabichromene (CBC) or/and the derivatives of thereof, and synthetic analogues, dexmedetomidine, (α2-AR) agonist, metabolic protectants, including, without limitation, vildagliptin, pristimerin, metformin, pyridoxamine, vasomodulators, epinephrine, rutin, isoxsuprine. The non-limiting list medicines exerting anti-tumor effect comprises, without limitation, chemotherapeutic agent, including without limitation cisplatin, carboplatin, chlorambucil, melphalan, nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, imatinib, nilotinib, dasatinib, and radicicol; an immunomodulatory agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analog, a DNA intercalating agent, anti-ageing agents, dipeptides, epigenetic factors and modulators, metformin, rapamycin, valproic acid or salt, wortmannin, polyamine spermidine, HDAC inhibitors sodium butyrate, butyric acid, sirtuin activators, resveratrol, co-enzyme CoQ1, small dicarboxylic acids, aspirin, salicylic, benzoic acid, carnitine analogues, human growth hormone, a topoisomerase analogue, an antibody, a cytokine, a folate antimetabolite, anti-glycolisis agent, inhibitor oligonucleotide to a human oncogenic or proto-oncogenic transcription factor, chemotherapeutic agent, an immunomodulatory agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analogue, a DNA intercalating agent, a topoisomerase analog, an antibody, a cytokine, or a folate antimetabolite, hexokinase inhibitor, a lactate dehydrogenase inhibitor, a phosphofructokinase 2 or phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibitor, a pyruvate kinase M2 inhibitor, a transketolase inhibitor, a pyruvate dehydrogenase inhibitor, a pyruvate dehydrogenase kinase inhibitor, a glucose-6-phosphate dehydrogenase inhibitor, a GLUT inhibitor, a proton transport inhibitor, a monocarboxylate transporter inhibitor, a hypoxia-inducible factor 1 alpha inhibitor, an AMP-activated protein kinase inhibitor, a glutamine inhibitor, an asparagine inhibitor, an arginine inhibitor, a fatty acid synthase inhibitor, an ATP-citrate lyase inhibitor, dimethyl malate, and malic enzyme 2 inhibitor, or any combination thereof. As used herein, the term “sample of gut microbiota” refers, without limitation to a natural sample originating from GI tract of a human subject. The sample of the invention may be collected directly from the GI tract of the subject or from body waste excreted from the body, such as feces. In one embodiment, the protocol comprises at least one episode of illuminating the sample at the wavelength in the range of 400 nm to 900 nm. In one embodiment, the protocol comprises at least one episode of illuminating the sample at the wavelength in the range of 420 nm to 880 nm. In one embodiment, the wavelength is 420-460 nm; 640-680 nm; and 830-870 nm. According to some embodiments, the wavelength 400 nm, 410 nm, 420 nm, 430 nm, 440 nm, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, 710 nm, 720 nm, 730 nm, 740 nm, 750 nm, 760 nm, 770 nm, 780 nm, 790 nm, 800 nm, 810 nm, 820 nm, 830 nm, 840 nm, 850 nm, 860 nm, 870 nm, 880 nm, 890 nm, and 900 nm. In one embodiment, the protocol comprises at least two illumination episodes. In yet another embodiment, the protocol comprises a sequence of illumination episodes. In another embodiment, similar wavelength is used in each illumination episode. In yet further embodiment, at least two illumination episodes are carried out at different wavelengths. For the sake of clarity, the protocol of the invention may involve as many illumination episodes as needed, at different or identical wavelengths and for the desired duration of time. Any combination of illumination at the indicated wavelengths with other parameters constitute an integral part of the present invention. In one embodiment, the protocol is designed to generate a specific profile of a plurality of bacterial species in the sample. Reference is now made to
FIG. 1 illustrating an exemplary embodiment of a heatmap presenting a profile of gut micro-organisms in a fecal sample at the genus level following illumination episodes with respect to the wavelength. Horizontal lines represent the relative abundance of major genera that exhibited at least 50% change relative to control. The bacterial abundance of each genus is expressed in standard deviation units scaled internally on a row basis and represented by color key. Hierarchical clustering was based on Euclidian distance measure and Word's agglomeration method. Side bars show the taxonomic classification of the different genera in the phylum, class, order and family level. A non-limiting list of gut micro-organisms in the sample comprises: bacterial species of Roseburia genus; Sutterella genus; Prevotella genus; Haemophilus genus; Anaerotruncus genus; Geobacter genus; Neisseria genus; Pseudomonas genus; Paraprevotella genus; Anaerostipes genus; Dehalobacterium genus; Coprococcus eutactus; Ruminococcus genus; Bifidobacterium longum; Dorea formicigenerans; Bacteroides caccae; and Parabacteroides gordonii. For the sake of clarity, and to avoid any doubt, any gut microorganism is an integral part of the present invention. According to some embodiments, the genus Roseburia, which consists of obligate gram-positive anaerobic bacterial species and includes five species: R. intestinalis, R. hominis, R. inulinivorans, R. faecis and R. cecicola, was increased in 440 nm treatment. According to some embodiments, the genus Sutterella, which represents gram negative anaerobic bacteria and includes three species: S. parvirubra, S. stercoricanis and S. wadsworthensis was increased in 660 nm and 880 nm treatments. According to some embodiments, the genus Prevotella which includes almost 40 different species with a large genomic diversity was increased in 660 nm and 880 nm treatments. According to some embodiments, the Geobacter species, Neisseria genus, and Pseudomonas genus, were reduced under all illumination treatments. - In one embodiment, the protocol is designed to enrich at least one microorganism genus in-vitro and/or in-vivo and/or in-situ. As used herein, the term “to enrich” refers, without limitation, to an increase in the proportion of a particular bacterial genus and/or species in the sample. In one embodiment, the protocol is designed to enrich at least one bacterial species. In one embodiment, the protocol is designed to enrich at least one bacterial genus. In one embodiment, the protocol is designed to increase the growth of at least one bacterial species and/or genus and to inhibit the growth of at least one bacterial species and/or genus at the same time. In yet another embodiment, the protocol is designed to increase the growth of more than one bacterial species and/or genii and to inhibit growth of more than one bacterial species and/or genii at the same time. In one embodiment, the protocol is designed to eliminate at least one bacterial species and/or genii. In one embodiment, the protocol is designed to downsize at least one bacterial species and/or genii. In one embodiment, the protocol is designed to obtain a human gut microbiota sample having a desired profile of bacterial species and/or genii. In one embodiment, the protocol. In one embodiment of the invention, the protocol is designed to selectively enhance, reduce or eliminate microorganism species from the sample to obtain a human gut microbiota sample having a desired profile. As used herein, the term “profile” refers, without limitation, to an information relating to characteristics of the sample based on quantification of bacterial species populations constituting the gut microbiota sample.
- The invention further provides A method for obtaining a sample having a desired profile of bacterial species of gut microbiota, the method comprising:
-
- a) providing a starting sample of bacterial species of gut microbiota;
- b) determining the profile of the bacterial species in the starting sample of gut microbiota;
- c) selecting at least one protocol designed to manipulate the growth of bacterial species, wherein said protocol comprises a predefined set of conditions, and, wherein said predefined set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
- d) subjecting the starting sample to the at least one protocol; and, optionally,
- e) determining the profile of the bacterial species in the sample.
- In one embodiment, the at least one protocol comprises at least two illumination episodes. In another embodiment, the at least one protocol comprises a sequence of multiple illumination episodes. In one embodiment, the wavelength of illumination is similar in each episode. In one embodiment, the wavelength of illumination is similar in each episode. In one embodiment, the wavelength of illumination is similar in each episode. In another embodiment, the illumination episodes are carried out at least two different wavelengths. In one embodiment, the at least one protocol is designed to enhance the growth of at least one bacterial species population in the starting sample. In another embodiment, the at least one protocol is designed to inhibit the growth of at least one bacterial species population in the starting sample. In another embodiment, the at least one protocol is designed to eliminate the growth of at least one bacterial species population in the starting sample. In one embodiment, the starting sample subjected to at least two protocols. In another embodiment, the at least two protocols are designed to manipulate growth of different bacterial species populations in the starting sample. In one embodiment, the wavelength is 420-460 nm; 640-680 nm; and 830-870 nm. According to some embodiments, the wavelength 400 nm, 410 nm, 420 nm, 430 nm, 440 nm, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, 710 nm, 720 nm, 730 nm, 740 nm, 750 nm, 760 nm, 770 nm, 780 nm, 790 nm, 800 nm, 810 nm, 820 nm, 830 nm, 840 nm, 850 nm, 860 nm, 870 nm, 880 nm, 890 nm, and 900 nm.
- In one embodiment, the at least one protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
- According to some embodiments, the invention provides a system for manipulating human gut microbiota in-situ comprising:
-
- a) a sample of human microbiota having desired bacterial species profile;
- b) a swallowable vehicle configured to move through the GI tract of a human subject, wherein said vehicle comprises at least one light emitting unit, and at least one reservoir configured to carry and release the sample of human microbiota;
- c) at least one protocol for manipulating the gut microbiota, wherein said protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
- d) a software operated controller configured to control the vehicle; and,
- e) a software configured to upload the at least one predefined set of conditions to the software operated controller.
- In one embodiment, the software operated controller is configured to fulfill at least one of the following functions: regulating the function of the light emitting unit, regulating the motion of the vehicle, identifying the location of the vehicle, instructing the vehicle to reach a desired location of the GI tract; delivering the at least one protocol for manipulating the gut microbiota at the desired location, and, actuating release of the cargo from the at least one reservoir at the desired location. comprises a plurality of light emitting elements configured to emit a light at the wavelength in the range of 400 nm to 900 nm. In one embodiment, the light emitting element is a light emitting diode (LED) or a laser beam. In one embodiment, the light emitting element is light emitting diode (LED). According to some embodiments, the system further comprises at least one thermo-electric element in communication with the controller, wherein said thermo-electric element is configured to control local temperature. In one embodiment, the at least one thermo-electric element configured to increase or decrease the local temperature. In another embodiment, the swallowable vehicle comprises at least two thermo-electric elements. In one embodiment the swallowable vehicle of the invention further comprises a second reservoir in communication with the controller and loaded with a liquid media and designed to release the liquid media in a desired location of the GI tract. In one embodiment, release of the liquid media from the second reservoir at the desired location results in a change in humidity. In one embodiment, the liquid media is water or saline. In one embodiment, the reservoir comprises a dispenser.
- According to some embodiments, the controller is configured to deliver two or more protocols for manipulating gut microbiota at the desired location. In one embodiment, the two or more protocols are delivered at the same location of the GI tract of the human subject. In yet another embodiment, the two or more protocols are delivered at different locations of the GI tract. In one embodiment, the controller is configured to deliver a plurality of protocols. In one embodiment, the plurality of protocols is delivered at different locations of the GI tract of the subject.
- The invention further provides a method for treating a disorder in a human subject by manipulating gut microbiota, the method comprising:
-
- a) providing a system for manipulating human gut microbiota in-situ, wherein said system comprises a swallowable light emitting vehicle configured to move through the GI tract of a human subject; a software; a software operated controller and a plurality of protocols for manipulating the gut microbiota, wherein each protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
- b) Selecting at least one of the plurality of protocols for manipulating gut microbiota suitable for treating the disorder;
- c) uploading said at least one protocol to the software operated controller of the vehicle;
- d) swallowing the vehicle; and
- e) delivering the at least one protocol for manipulating gut microbiota at a desired location of the GI tract of the subject.
- In one embodiment, the swallowable vehicle comprises at least one reservoir configured to carry and release a cargo. In another embodiment, further comprising the step of loading a sample derived from human gut microbiota having a desired profile of bacterial species to the at least one reservoir. In another embodiment, the step of loading the sample derived from gut microbiota to the reservoir precedes step d. In yet another embodiment, the method further comprising the step of releasing the sample derived from human gut microbiota or a portion thereof at the desired location of the GI tract of the subject. In one embodiment, the step of releasing the sample precedes step e. In another embodiment, the step of releasing the sample follows step e. In one embodiment, the protocol comprises multiple illumination episodes. In one embodiment, the software operated controller is configured to fulfill at least one of the following functions: regulating the function of the light emitting unit, regulating the motion of the vehicle, identifying the location of the vehicle, instructing the vehicle to reach a desired location of the GI tract; delivering the at least one protocol for manipulating the gut microbiota at the desired location, and, actuating release of the cargo from the at least one reservoir at the desired location. In yet another embodiment, the protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance. According to some embodiments, the non-limiting list of disorders of the invention includes: Inflammatory Bowel Diseases, Crohn Disease, Type II Diabetes, HIV, malignancy of GI tract, Ulcerative Colitis, Proctitis, Over-weight, Irritable Bowel syndrome, Alzheimer, depression, Celiac, Specific food allergies, Clostridium Difficile infection, Diarrhea, Chronic constipation, and Dysbiosis.
- The invention further provides a method of fecal transplantation in a subject comprising:
-
- a) preparing a fecal sample suitable for transplantation at the GI tract of the subject;
- b) providing a swallowable vehicle configured to move through the GI tract of a human subject, wherein said vehicle comprises at least one light emitting unit, a software operated controller, and at least one reservoir configured to carry and release the fecal sample;
- c) loading the reservoir with the fecal sample;
- d) programming the software operated controller to deliver the fecal sample to a desired location in the GI tract;
- e) swallowing the vehicle; and,
- f) releasing the fecal sample at the desired location of the GI tract.
- As used herein, the term “preparing a fecal sample” refers, without limitation, to subjecting the fecal sample to at least one protocol of the invention to obtain a sample having desired profile of bacterial species. In one embodiment, the method of fecal transplantation further comprises a step of delivery of at least one protocol for manipulating gut microbiota. In one embodiment, the protocol comprises at least one episode of illuminating the GI tract of the subject at the wavelength in the range of 400 nm to 900 nm. In one embodiment, the protocol comprises multiple illuminating episodes. According to one embodiment, the protocol comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, presence of bioactive substance, or a combination thereof.
- According to some embodiments, the subject is afflicted with a disorder characterized by impaired gut microbiota. A non-limiting list of disorders characterized by impaired gut microbiota includes: Inflammatory Bowel Diseases, Crohn Disease, Type II Diabetes, HIV, malignancy of GI tract, Ulcerative Colitis, Proctitis, Over-weight, Irritable Bowel syndrome, Alzheimer, depression, Celiac, Specific food allergies, Clostridium Difficile infection, Diarrhea, Chronic constipation, and Dysbiosis.
- The objective of the study was to test the effect of three different wavelengths of low-level light therapy on fecal microbiota composition in-vitro.
-
-
- 1. Long term illumination exposure of the different tested regimens to assess microbial composition change following treatment.
- 2. Short term experiment combining bacterial composition assessment and inflammatory related function.
- 3. C. difficile toxicogenic strain experiment, to evaluate the specific effect of LLLT on the bacterium growth.
Framework 1: Long Term Experiment with Longitudinal Illumination Exposure
- The tested regimens with regard to the Illumination wavelengths and exposure times are detailed in table 2. Illumination was performed in 5 exposures, where in each day, 2 exposures were performed (same time every day, at least 8 hours interval between exposures. i.e. 8:00 am and 16:00 pm) for 2.5 days.
-
TABLE 2 The different tested illumination regimens* Regimen Wavelength Exposure time (sec) 1 440 nm 50 2 660 nm 60 3 850 mm 110 4 control - Sample size: 10 fecal samples were tested for each regimen. A total of 40 tested samples+original pre-plated uncultured sample.
-
-
- 1. Preparation of the Fecal Sample
- a. The fecal sample were collected (preferentially from individuals that were not treated with antibiotics in the last year) in sterile specimen and immediately were frozen in −20° C. While being transported to the lab, the stool samples were retained in anaerobic jar with gas pack, within a container with ice or dry ice b. In the lab, the samples were be stored in −80° C.
- 2. Culturing of Fecal Sample
- a. For culturing, samples were placed in anaerobic chamber and be adjusted to room temperature.
- b. Inside an anaerobic chamber, 0.2 g of fecal sample was diluted in 1800 μl of pre-reduced liquid medium (BHI with supplements).
- c. The fecal material was suspended by vortexing for 5 min.
- d. The fecal suspension was standing at room temperature for 5 min to allow the precipitation of insoluble ingredients.
- e. Then 50 μl of the suspension were plated on the agar plates (size 35 mm) followed by incubation in anaerobic conditions at 37° C. for 3 days in which they were exposed to the illumination treatment twice a day as detailed above.
- f. Samples were incubated in a dark place between illumination exposures.
- g. 500 μl of the starting fecal suspension were stored as a frozen stock at −80° C. by the addition of glycerol to reach a final concentration of 25% glycerol (equal volume of bacterial suspension in growth media, and 1:1 pre-reduced glycerol with PBS) for optional bacterial composition assessment.
- 3. Illumination Treatment
- 1. Preparation of the Fecal Sample
- Illumination was performed in 5 exposures, where in each day, 2 exposures were performed (same time every day, at least 8 hr. interval between exposures. i.e. 8:00 am and 16:00 pm) for 2.5 days within the anaerobic chamber. After the 5th exposure, a 6-hour duration between illumination and bacterial harvesting is required. Illumination device was held in a specific pre-defined distance from the plate (using a special holder), in order to equally expose all the plate surface.
-
- 4. Bacterial Harvesting at End Point
- a. 0.5 ml of liquid media (BHI) were added to each plate and bacterial colonies were scraped and suspended in the liquid medium.
- b. 250 μl of the harvested bacteria, were added to equal volume of 1:1 glycerol with PBS (25% glycerol final conc.) and were frozen at −80° C. for RNA extraction.
- c. The rest of the fecal suspension were collected and stored in the same manner as detailed in stage 4.b for the next experiment of co-culture.
Framework 2: Short Term Experiment with Assessment of Bacterial-Host Function Post Treatment
- 4. Bacterial Harvesting at End Point
- To isolate the direct effect of the illumination treated fecal microbiota, effects of non-treated and treated fecal microbiota (obtained in experiment 1) on epithelial cells using co-cultures were tested.
-
- 1. Pre-Growth of HT-29 Cells:
- a. 1 ml of thawed HT-29 stock at a concentration of 3-4*106 cells/ml were suspended in 9 ml pre warmed McCoy medium supplemented with 10% (v/v) inactivated FCS (fetal calf serum) and 2 mM glutamine to wash the DMSO.
- b. Then cells were centrifuged at 125 g, at room temperature, for 10 min.
- c. The medium were aspirated and suspended in 10 ml McCoy medium supplemented with 10% (v/v) FCS and 2 mM glutamine.
- d. Cells were plated in T-25 cm2 flask. The cells were incubated in 37° C. for 2-4 days in 5% CO2 air atmosphere.
- e. The cells were harvested when reaching 80-90% confluent growth as follows: cells were detached from the flask by aspiration of the medium and the addition of 1 ml trypsin (0.25% w/v trypsin-0.53 mM EDTA) followed by incubation for 5 min in 37° C. Cells detachment was visualized under microscope.
- f. To stop the trypsin activity 1 ml of McCoy medium supplemented with 10% (v/v) FCS and 2 mM glutamine were added.
- g. Then medium was added accordingly to obtain a final concentration of 5×106 cells/ml.
- 2. Co-Culture
- a. HT29 colonic epithelial cells were seeded at a density of 5×104 cells/cm2 onto 24-well plates in 1 ml McCoy medium supplemented with 10% inactivated FCS and 2 mM glutamine and grown at 37° C. in 5% CO2 and 95% air for 24 hr.
- b. For co-culture, the medium were changed to reduced media and 100 μl of fecal bacterial suspensions from experiment 1 were added to each well of a 24-well plate.
- c. Co-cultures were incubated at 37° C. for 6 hrs. under anaerobic conditions.
- d. At experiment end-point:
- a) The bacterial cell suspension was collected from each well (the HT29 will be attached to the bottom). 500 μl of the bacteria suspension was added to equal volume of 1:1 glycerol with PBS (25% glycerol final conc.) and will be frozen at −80° C. for RNA extraction.
- b) Then, 350 μl cell lysis reagent (RLT buffer+ beta mercaptoethanol) that was used in the first step of RNA extraction procedure (QIAGEN) was added to each well. Cells were scraped from the well in order to be transferred to the lysis buffer.
- c) Next extraction steps were followed immediately according to the manufacturer's instruction. The extracted RNA will be preserved in −80° C. for assessment of inflammatory cytokine expression using real time PCR.
Framework 3: The Effect of Illumination Treatment on the Growth of Toxigenic C. difficile.
C. difficile Strain Selection:
- 1. Pre-Growth of HT-29 Cells:
- Toxigenic strain of C. difficile that expresses both the tcdA and tcdB genes required for the production of toxin A and toxin B: Clostridioides difficile (Prevot) Lawson et al. (ATCC® 43255™) that belongs to
toxinotype 0 was used. - C. difficile inhibition was compared to a reference beneficial species such as Bifidobacterium longum that was reported to reduce mucosal inflammation marker in IBD (can be grown on MRS at 37° C. anaerobically)3
-
- 1. Recovery of C. difficile stock was performed according to the ATCC instructions.
- 2. C. difficile was plated on brain heart infusion broth supplemented with yeast extract (0.5%, wt/vol) and 1-cysteine (10%, wt/vol) (BHIS—Brain heart infusion—supplemented), and were incubated at 37° C. under anaerobic condition for 48 h, as previously reported4,5.
- 3. Illumination treatment:
- a. C. difficile culture was adjusted to an optical density of 0.5 at 600 nm (OD600) (mid exponential phase).
- b. The adjusted culture was split into 4 sample falcons, each falcon for each tested illumination treatment.
- c. The adjusted culture was poured into a sterile dish with high surface area to obtain a low bacterial suspension height (about 0.5 cm) under aseptic conditions in anaerobic chamber.
- d. Illumination exposure was performed as detailed in the table below (single treatment with different duration exposures is recommended if possible):
-
TABLE 3 The different tested illumination treatments in the C. difficile experiment Regimen Wavelength Exposure time (sec) 1 440 nm 50 2 660 nm 60 3 850 nm 110 4 control -
- a. Optical density (at 600 nm) of C. difficile cultures after illumination treatments and control were measured periodically during anaerobic cultivation for 48 hr at 37° C. to evaluate growth (using plate reader if available).
- b. 0, 12, 24, 36, 48 hr post illumination exposure, 500 μl of C. difficile cultures were used serial dilutions and plating (100 μl) on BHIS agar plates and parallel measurement of OD, for the evaluation of CFU (colony forming units) ml−1. Plates will be incubated anaerobically in 37° C. for 48 hr. The CFU/ml/OD600 were determined and extrapolated to the other OD measurements for CFU quantification based on OD.
-
FIG. 2 demonstrates that the treatment (660 nm & 850 nm) induces significant alternations in microbiota composition compared to the control. (A) PCoA (principal coordinates analysis) presenting microbiota composition was used to assess microbial composition dissimilarity based on Bray-Curtis distance. Each point represents the bacterial composition profile of the different tested treatment protocols: 440 nm wavelength (blue); 660 nm (orange); 850 nm (red) and untreated sample as a control (dark green). Numbers indicated different fecal donors. (B) Boxplots comparing PC1 and PC2 coordinates between the different treatments. The results demonstrate that the treatment (660 nm & 850 nm) induces significant alternations in microbiota composition compared to the control, as indicated from the significant difference in PC2 coordinates values. -
FIG. 3 demonstrates that the treatment increases the microbial diversity of IBD samples using alpha diversity (community richness) rarefaction plots by treatment. Microbial alpha diversity was assessed using rarefaction plots to compare samples from the different treatments and control using the Faith's Phylogenetic Diversity estimate. Error bars correspond to variations between samples of each treatment group. (A) 440 nm treatment induces increase in microbial diversity in IBD samples. (B) 660 nm treatment induces increase in microbial diversity in IBD samples. (C) 850 nm treatment has no significant effect on alpha diversity. Healthy samples were not affected due to already high baseline diversity. The results indicate that the 440 nm and the 660 nm treatments induce increase in the microbial diversity of samples from IBD patients to similar level of samples from healthy donors. -
FIG. 4 demonstrates that the treatment increases the microbial diversity of IBD samples. Microbial alpha diversity was assessed using rarefaction plots to compare samples from the different treatments and control using the observed OTU (Operational Taxonomic Units) estimate, which represent the count of unique OTUs in each sample. Error bars correspond to variations between samples of each treatment group. (A) 440 nm treatment induces increase in microbial diversity in IBD samples. (B) 660 nm treatment has no significant effect on alpha diversity. (C) 850 nm treatment has no significant effect on alpha diversity. Healthy samples are not affected due to already high baseline diversity. The results indicate that the 440 nm and the 660 nm treatments induce increase in the microbial diversity of samples from IBD patients to similar level of samples from healthy donors. -
FIG. 5 illustrates treatment differentially abundant species. Boxplots comparing the normalized relative abundance levels of differentially abundant species between treatment samples and controls. The normalization was performed by first calculation of relative abundance of each species within each sample multiply by factor 1000. Only samples that had non-zero counts in the control untreated group, in at least 30% of the samples were included. Differential abundance was estimated using paired Wilcoxon test between treated samples vs controls. The results demonstrate a significant increase in the Lachnospiraceae sp. and Ruminococcus lactaris abundances following 440 nm and 660 nm treatments. Lachnospiraceae and Ruminococcaceae were known to be positively associated with healthy individuals. Some species of the Lachnospiraceae family are butyrate producers; butyrate production in the human gut is highly relevant as it promotes Treg cell differentiation which can ultimately suppress pro-inflammatory responses. -
FIG. 6 illustrates treatment differential abundance—Family level. Boxplots comparing the normalized relative abundance levels of differentially abundant bacteria in the family level between treatment samples and controls. The normalization was performed by first calculation of relative abundance of each species within each sample multiply by factor 1000. Only samples that had non-zero counts in the control untreated group, in at least 30% of the samples were included. Differential abundance was estimated using paired Wilcoxon test between treated samples vs controls. The results indicate a significant increase in the abundance of the Lachnospiraceae family following 440 nm and 660 nm treatments. Lachnospiraceae are important short-chain fatty acids producers. - The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a,” “an” and “the” are intended to include plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements components and/or groups or combinations thereof, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups or combinations thereof. As used herein the terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”. The term “consisting of” means “including and limited to”.
- As used herein, the term “and/or” includes any and all possible combinations or one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
- Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and claims and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. Well-known functions or constructions may not be described in detail for brevity and/or clarity.
- It will be understood that when an element is referred to as being “on,” “attached” to, “operatively coupled” to, “operatively linked” to, “operatively engaged” with, “connected” to, “coupled” with, “contacting,” etc., another element, it can be directly on, attached to, connected to, operatively coupled to, operatively engaged with, coupled with and/or contacting the other element or intervening elements can also be present. In contrast, when an element is referred to as being “directly contacting” another element, there are no intervening elements present.
- It will be understood that, terms such as, for example, “processing”, “computing”, “calculating”, “determining”, “establishing”, “analyzing”, “checking”, or the like, may refer to operation(s) and/or process(es) of a computer, a computing platform, a computing system, or other electronic computing device, that manipulates and/or transforms data represented as physical (e.g., electronic) quantities within the computer's registers and/or memories into other data similarly represented as physical quantities within the computer's registers and/or memories or other information non-transitory storage medium that may store instructions to perform operations and/or processes. It will be understood that, although the terms first, second, etc., may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms. Rather, these terms are only used to distinguish one element, component, region, layer and/or section, from another element, component, region, layer and/or section.
- Certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
- Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention.
- Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
- Whenever terms “plurality” and “a plurality” are used it is meant to include, for example, “multiple” or “two or more”. The terms “plurality” or “a plurality” may be used throughout the specification to describe two or more components, devices, elements, units, parameters, or the like. The term set when used herein may include one or more items. Unless explicitly stated, the method embodiments described herein are not constrained to a particular order or sequence. Additionally, some of the described method embodiments or elements thereof can occur or be performed simultaneously, at the same point in time, or concurrently.
- As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- By “patient” or “subject” is meant to include any mammal. A “mammal,” as used herein, refers to any animal classified as a mammal, including but not limited to, humans, experimental animals including monkeys, rats, mice, and guinea pigs, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, and the like.
- “Treating” or “treatment” of a disease as used herein includes: preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms, or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
- In case of conflict, the patent specification, including definitions, will prevail. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Throughout this application various publications, published patent applications and published patents are referenced.
- It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather the scope of the present invention is defined by the appended claims and includes both combinations and sub-combinations of the various features described hereinabove as well as variations and modifications thereof, which would occur to persons skilled in the art upon reading the foregoing description.
Claims (53)
1. A method for manipulating the growth of a plurality of bacterial species of gut microbiota comprising subjecting the plurality of bacterial species to at least one protocol, wherein said protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm.
2. The method of claim 1 , wherein manipulating the growth of the plurality of bacterial species of gut microbiota: a) comprises obtaining a sample of gut microbiota from a subject and, subjecting said sample to the at least one protocol comprising at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm; or, b) is done in-situ and comprises subjecting at least a portion of GI tract of a subject to the at least one protocol comprising at least one episode of illumination at the wavelength in the range of 400 nm to 900 nm.
3. (canceled)
4. (canceled)
5. The method of claim 1 , wherein manipulating the growth of the plurality of bacterial species of gut microbiota comprises inhibiting the growth of at least one of the plurality of the bacterial species; eliminating at least one of the plurality of the bacterial species; enhancing the growth of at least one of the plurality of the bacterial species; or a combination thereof; and, optionally, wherein the at least protocol is designed to create a specific profile of the bacterial species.
6. (canceled)
7. (canceled)
8. (canceled)
9. The method of claim 1 , wherein the at least one protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
10. A method for obtaining a sample having a desired profile of bacterial species of gut microbiota, the method comprising:
a) providing a starting sample of bacterial species of gut microbiota;
b) determining the profile of the bacterial species in the starting sample of gut microbiota;
c) selecting at least one protocol designed to manipulate the growth of bacterial species,
wherein said at least one protocol comprises a predefined set of conditions, and,
wherein said predefined set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
d) subjecting the starting sample to the at least one protocol; and, optionally,
e) determining the profile of the bacterial species in the sample.
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. The method of claim 10 , wherein the at least one protocol is designed to: enhance growth of at least one type of bacterial species in the starting sample; inhibit growth of at least one type of bacterial species in the starting sample; downsize at least one type of bacterial species in the starting sample; or a combination thereof; and,
optionally, wherein when the starting sample is subjected to two or more protocols, each protocol is designed to manipulate growth of different bacterial species.
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. The method of claim 10 , wherein the at least one protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
22. The method of claim 10 , wherein the wavelength is in the range selected from of 420-460 nm; 640-680 nm; and 830-880 nm.
23. (canceled)
24. (canceled)
25. A system for manipulating human gut microbiota in-situ comprising:
a) a sample of human microbiota having desired bacterial species profile;
b) a swallowable vehicle configured to move through the GI tract of a human subject, wherein said vehicle comprises at least one light emitting unit, and at least one reservoir configured to carry and release the sample of human microbiota;
c) at least one protocol for manipulating the gut microbiota, wherein said at least one protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm;
d) a software operated controller configured to control the vehicle; and,
e) a software configured to upload the predefined set of conditions to the software operated controller.
26. The system of claim 25 , wherein the software operated controller is configured to fulfill at least one of the following functions: regulating the function of the light emitting unit, regulating the motion of the vehicle, identifying the location of the vehicle, instructing the vehicle to reach a desired location of the GI tract; delivering the at least one protocol for manipulating the gut microbiota at the desired location, and, actuating release of the cargo from the at least one reservoir at the desired location; and, optionally, wherein when the controller is configured to deliver two or more protocols, the two or more protocols are delivered at the same location of the GI tract or at the different locations of the GI tract.
27. (canceled)
28. (canceled)
29. The system of claim 25 , wherein the system further comprises at least one thermo-electric element in communication with the controller, wherein said thermo-electric element is configured to control local temperature; and, optionally wherein the vehicle further comprises a second reservoir in communication with the controller, said reservoir is loaded with a liquid media, wherein said liquid media is optionally released from the second reservoir at the desired location.
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. A method for treating a disorder in a human subject by manipulating gut microbiota, the method comprising:
a) providing a system for manipulating human gut microbiota in-situ, according to claim 25 ;
b) Selecting at least one of the plurality of protocols for manipulating gut microbiota suitable for treating the disorder;
c) uploading said at least one protocol to the software operated controller of the vehicle;
d) swallowing the vehicle; and
e) delivering the at least one protocol for manipulating gut microbiota at a desired location of the GI tract of the subject.
38. (canceled)
39. The method of claim 37 , further comprising the steps of loading a sample derived from human gut microbiota having a desired profile of bacterial species to the at least one reservoir and, optionally releasing the sample derived from human gut microbiota or a portion thereof at the desired location of the GI tract of the subject.
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. The method of claim 37 , wherein the software operated controller is configured to fulfill at least one of the following functions: regulating the function of the light emitting unit, regulating the motion of the vehicle, identifying the location of the vehicle, instructing the vehicle to reach a desired location of the GI tract; delivering the at least one protocol for manipulating the gut microbiota at the desired location, and, actuating release of the cargo from the at least one reservoir at the desired location.
46. The method of claim 37 , wherein the at least one protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
47. The method of claim 37 , wherein the disorder is selected from the group consisting of Inflammatory Bowel Diseases; Crohn Disease; Type II Diabetes; HIV; malignancy of GI tract; Ulcerative Colitis; Proctitis; Over-weight; Irritable Bowel syndrome; Alzheimer; depression; Celiac; Specific food allergies; Clostridium Difficile infection; Diarrhea; Chronic constipation; Dysbiosis.
48. A method of fecal transplantation in a subject comprising:
f) preparing a fecal sample suitable for transplantation at the GI tract of the subject
g) providing a swallowable vehicle configured to move through the GI tract of a human subject, wherein said vehicle comprises at least one light emitting unit, a software operated controller, and at least one reservoir configured to carry and release the fecal sample;
h) loading the reservoir with the fecal sample;
i) programming the software operated controller to deliver the fecal sample to a desired location in the GI tract;
j) swallowing the vehicle; and,
k) releasing the fecal sample at the desired location of the GI tract; and, optionally,
l) delivering at least one protocol for manipulating gut microbiota, wherein each protocol comprises a predefined set of conditions, and, wherein said set of conditions comprises at least one illumination episode at the wavelength in the range of 400 nm to 900 nm.
49. (canceled)
50. (canceled)
51. The method of claim 48 , wherein the at least one protocol further comprises at least one of the parameters selected from the group consisting of illumination doses, wavelengths, duration of each illumination, number of illumination episodes, frequency of illumination episodes, exposure to oxygen, humidity, exposure to acoustic wave, pH, exposure to radio frequency, temperature, presence of medication, presence of bacterial species, and presence of bioactive substance.
52. The method of claim 48 , wherein the subject is afflicted with a disorder characterized by impaired gut microbiota.
53. The method of claim 52 , wherein the disorder is selected from the group consisting of Inflammatory Bowel Diseases; Crohn Disease; Type II Diabetes; HIV; malignancy of GI tract; Ulcerative Colitis; Proctitis; Over-weight; Irritable Bowel syndrome; Alzheimer; depression; Celiac; Specific food allergies; Clostridium Difficile infection; Diarrhea; Chronic constipation; and Dysbiosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/436,222 US20220152413A1 (en) | 2019-03-04 | 2020-03-03 | Method and device for gut microbiota manipulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962813543P | 2019-03-04 | 2019-03-04 | |
US17/436,222 US20220152413A1 (en) | 2019-03-04 | 2020-03-03 | Method and device for gut microbiota manipulation |
PCT/IL2020/050239 WO2020178819A1 (en) | 2019-03-04 | 2020-03-03 | Method and device for gut microbiota manipulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220152413A1 true US20220152413A1 (en) | 2022-05-19 |
Family
ID=72337591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/436,222 Pending US20220152413A1 (en) | 2019-03-04 | 2020-03-03 | Method and device for gut microbiota manipulation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220152413A1 (en) |
EP (2) | EP4241787A3 (en) |
JP (1) | JP2022523565A (en) |
CN (1) | CN113660978A (en) |
WO (1) | WO2020178819A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022185323A1 (en) * | 2021-03-05 | 2022-09-09 | Photopill Medical Ltd | Device and method for gastrointestinal location estimation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030191459A1 (en) * | 1999-06-23 | 2003-10-09 | Ganz Robert A. | Apparatus and method for debilitating or killing microorganisms within the body |
US20120226335A1 (en) * | 2009-11-06 | 2012-09-06 | Universita' Degli Studi Di Firenze | Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections |
US20120253204A1 (en) * | 2010-03-17 | 2012-10-04 | Photopill Medical Ltd. | Systems and methods for phototherapeutic treatment of rectal diseases |
US20130013031A1 (en) * | 2010-03-17 | 2013-01-10 | Photopill Medical Ltd. | Capsule phototherapy |
US20140005758A1 (en) * | 2010-03-17 | 2014-01-02 | Photopill Medical Ltd. | Capsule phototherapy |
US20140081360A1 (en) * | 2012-09-20 | 2014-03-20 | Photopill Medical Ltd. | Capsule phototherapy |
US20160151639A1 (en) * | 2013-07-10 | 2016-06-02 | Oxys Ag | Devices and methods for delivery of therapeutic energy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7390668B2 (en) * | 1996-10-30 | 2008-06-24 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for photodynamic treatment of disease |
KR101406370B1 (en) * | 2012-11-01 | 2014-06-12 | 가톨릭대학교 산학협력단 | Capsule endoscope for photodynamic and sonodynamic therapy |
EP3367875A1 (en) * | 2015-10-29 | 2018-09-05 | Elwha LLC | Lumen traveling device |
WO2019093787A2 (en) * | 2017-11-08 | 2019-05-16 | 서울바이오시스주식회사 | Medical capsule device |
-
2020
- 2020-03-03 US US17/436,222 patent/US20220152413A1/en active Pending
- 2020-03-03 EP EP23182605.8A patent/EP4241787A3/en active Pending
- 2020-03-03 WO PCT/IL2020/050239 patent/WO2020178819A1/en unknown
- 2020-03-03 CN CN202080018803.3A patent/CN113660978A/en active Pending
- 2020-03-03 JP JP2021552776A patent/JP2022523565A/en active Pending
- 2020-03-03 EP EP20766447.5A patent/EP3934747A4/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030191459A1 (en) * | 1999-06-23 | 2003-10-09 | Ganz Robert A. | Apparatus and method for debilitating or killing microorganisms within the body |
US20120226335A1 (en) * | 2009-11-06 | 2012-09-06 | Universita' Degli Studi Di Firenze | Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections |
US20120253204A1 (en) * | 2010-03-17 | 2012-10-04 | Photopill Medical Ltd. | Systems and methods for phototherapeutic treatment of rectal diseases |
US20130013031A1 (en) * | 2010-03-17 | 2013-01-10 | Photopill Medical Ltd. | Capsule phototherapy |
US20140005758A1 (en) * | 2010-03-17 | 2014-01-02 | Photopill Medical Ltd. | Capsule phototherapy |
US20140081360A1 (en) * | 2012-09-20 | 2014-03-20 | Photopill Medical Ltd. | Capsule phototherapy |
US20160151639A1 (en) * | 2013-07-10 | 2016-06-02 | Oxys Ag | Devices and methods for delivery of therapeutic energy |
Also Published As
Publication number | Publication date |
---|---|
EP4241787A2 (en) | 2023-09-13 |
EP3934747A4 (en) | 2022-05-04 |
EP3934747A1 (en) | 2022-01-12 |
JP2022523565A (en) | 2022-04-25 |
WO2020178819A1 (en) | 2020-09-10 |
CN113660978A (en) | 2021-11-16 |
EP4241787A3 (en) | 2024-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lagier et al. | Culturing the human microbiota and culturomics | |
Tovaglieri et al. | Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites | |
Reese et al. | Antibiotic-induced changes in the microbiota disrupt redox dynamics in the gut | |
Kohl et al. | Inoculation of tannin‐degrading bacteria into novel hosts increases performance on tannin‐rich diets | |
Elbehiry et al. | Acinetobacter baumannii as a community foodborne pathogen: Peptide mass fingerprinting analysis, genotypic of biofilm formation and phenotypic pattern of antimicrobial resistance | |
Park et al. | Do ruminal ciliates select their preys and prokaryotic symbionts? | |
CN104024430A (en) | Methods for diagnosing and treating cardiac defects | |
US10788452B2 (en) | High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications | |
US20220152413A1 (en) | Method and device for gut microbiota manipulation | |
Tvrdá et al. | The impact of bacteriocenoses on sperm vitality, immunological and oxidative characteristics of ram ejaculates: does the breed play a role? | |
Hendrick et al. | Efficacy of monensin sodium for the reduction of fecal shedding of Mycobacterium avium subsp. paratuberculosis in infected dairy cattle | |
Marker et al. | Short-term effect of oral amoxicillin treatment on the gut microbial community composition in farm mink (Neovison vison) | |
US20200263227A1 (en) | High resolution systems, kits, apparatus, and methods using magnetic beads for high throughput microbiology applications | |
AU2017335897A1 (en) | High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications | |
AU2017289055A1 (en) | High resolution systems, kits, apparatus, and methods using magnetic beads for high throughput microbiology applications | |
Shang et al. | Environmental exposure to swine farms reshapes human gut microbiota | |
Wythe et al. | Advancements in Poultry Nutrition and Genetics, the Role of Antibiotic Growth Promoters, and the Introduction of Feed Additive Alternatives | |
Xu et al. | Visualizing germination of microbiota endospores in the mammalian gut | |
Rajakumari et al. | Zebrafish: A novel model organism to assess probiotics influence on growth and development | |
Li et al. | Effects of starter feeds of different physical forms on rumen fermentation and microbial composition for pre-weaning and post-weaning lambs | |
Sachuk et al. | The current state of development and veterinary support of pheasant farming in Ukraine | |
Chai et al. | Effect of weaning time on growth performance and rumen development of Hu lambs | |
Svensson et al. | Metformins effekt på bukspyttkjertel kreftcellelinjene Panc-1 og MIA-Pa-Ca-2 | |
Bernier et al. | Microfluidic platform for microbial spore germination studies in multiple growth conditions | |
Wilson | Characterizing the Impact of Select Bacterial Isolates on Perinatal Pioneer Microbial Colonization and GIT Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHOTOPILL MEDICAL LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEN YEHUDA, SHARON;BEN YEHUDA, RAM;REEL/FRAME:057387/0939 Effective date: 20210824 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |